Table 3.

Patient's characteristics among positive and negative anti-IFX antibodies.

	Positive anti-IFX antibodies	Negative anti-IFX antibodies	P value
Disease duration, mean, and months	90.77 ± 49.56	128 ± 97.48	0.306
IFX treatment duration, mean, and months	29.77 ± 17.01	38.77 ± 34.60	0.511
DAS28 at flare and mean	5.09 ± 1.19	4.18 ± 1.67	0.189
DAS28 after 2 months and mean	5.68 ± 0.8	3.95 ± 1.49	0.006
csDMARD association and nr (%)	3	9	0.028

Differences between patient's characteristics were tested by Student's t-test or chi-square test.

IFX: infliximab; csDMARD: conventional synthetic disease modifying antirheumatic drug.